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Abstract 
Three randomised, blinded and placebo-controlled 
laboratory studies were conducted to evaluate the 
efficacy of emodepside plus toltrazuril suspension 
(Procox® suspension for dogs) against Isospora 
canis and Isospora ohioensis-complex. Unweaned 
puppies were experimentally infected with sporu-
lated oocysts of I. canis and/or I. ohioensis-complex. 
In each study, one group was treated during prepa-
tency (2 or 4 days post infection) while dogs in the 
second group were treated individually after the 
onset of oocyst excretion of the respective coccidia 
species. The dogs were treated with the minimum 
therapeutic dose of 0.45 mg emodepside and 9 mg 
toltrazuril per kg body weight. Daily faecal oocyst 
counts from both groups were compared to placebo-
treated control groups to determine efficacy.
Dogs treated during prepatent I. canis or I. ohio-
ensis-complex infection showed significantly lower 
oocyst counts for up to 12 days compared to the 
control group. Oocyst counts were reduced by 
90.2 – 100 % while the control groups continued to 
exhibit an adequate infection, except for one study 
where efficacy against prepatent I. canis infection 
faded 13 days after treatment. Following treatment 
of patent I. canis or I. ohioensis-complex infections, 
significantly lowered oocyst counts were observed 
for up to 9 days compared to the control group. Fae-
cal oocyst counts were reduced by 91.5 – 100 %. In 
all three studies the number of days with diarrhoea 
was significantly lower when dogs were treated 
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Fig. 3   Oocysts of Isospora ohioensis-complex – 
scale bar 20 µm. © Bayer
Fig. 1   Watery diarrhoea as a result of Isospora spp. 
infection
during prepatent Isospora spp. infection compared 
to the control groups. No adverse drug reactions 
were observed during the studies. In conclusion, 
the studies demonstrated that emodepside plus 
toltrazuril suspension is an efficient coccidiocide 
for dogs.
Introduction
Isospora spp. are the causative agents of canine 
coccidiosis. Clinical coccidiosis mainly affects pup-
pies and immunocompromised dogs with watery, 
sometimes haemorrhagic diarrhoea (Fig. 1) being 
the most prominent clinical sign besides vomiting, 
abdominal discomfort and inappentence (Lappin 
2010). Depending on the age of the animal, immune 
status and the parasite burden, severe dehydra-
tion and death can occur (Lappin 2010; Daugschies 
2000). While infection often takes a subclinical 
course, even moderate intestinal damage as a 
result of Isospora spp. infection may considerably 
alter growth and development of a puppy (Daug-
schies et al. 2000) so that the significance of Isos-
pora spp. infections should not be underestimated. 
Four Isospora species can be found in dogs: I. canis, 
I. ohioensis, I. burrowsi and I. neorivolta (Figs. 2 and 3). 
The three latter species are often referred to as the 
I. ohioensis-complex because they cannot be reli-
ably differentiated by the size or structure of their 
oocysts (Lindsay et al. 1997). Although other ways 
of infection (for example via paratenic hosts) are 
possible, puppies and young dogs mainly become 
infected by ingestion of sporulated oocysts from 
their environment, e.g. from their litter mates with 
the bitch potentially serving as a reservoir (Daug-
schies et al. 2000; Buehl et al. 2006). The life cycle 
of Isospora spp. in the dog has been reviewed by 
Lindsay et al. (1997), Dubey et al. (2009) and oth-
ers. Following excystation in the gut, cells of the 
intestinal mucosa are invaded and asexual repro-
duction (schizogony) takes place. This process is 
repeated several times before immature oocysts 
form in the sexual phase of the development cycle 
Fig. 2   Oocysts of Isospora canis – scale bar 20 µm. © Bayer
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(gamogony). Schizogony and gamogony cause dam-
age to the intestinal mucosa resulting in the above 
described clinical signs of enteritis. After matura-
tion unsporulated oocysts are excreted in the faeces. 
The prepatent period after ingestion of infective 
oocysts is described to be 8 – 12 days for I. canis 
and 4 – 9 days for I. ohioensis-complex (Becker et al. 
1981; Rommel and Zielasko 1981; Baek et al. 1993; 
Buehl et al. 2006; Mitchell et al. 2007). Sporulation 
of oocysts passed with the faeces can take place 
within a few days (Fisher 2002). The sporulated 
Isospora spp. oocysts can then stay infective for 
months and are frequently resistant to disinfec-
tion so that, although basic hygiene measures like 
disinfection and frequent removal of faeces are 
recommended, they cannot completely control the 
contamination of the environment with oocysts 
(Barutzki et al. 1981; Buehl et al. 2006; Tenter and 
Deplazes 2006). Therefore, reduction/prevention of 
oocyst excretion by anticoccidial treatment of dogs 
is considered to be an essential means to interrupt 
the life cycle and reduce infection pressure (Daug-
schies et al. 2000; Buehl et al. 2006).
Emodepside plus toltrazuril suspension (Procox® 
suspension for dogs) was developed to provide 
a treatment option for dogs, especially puppies 
and young dogs, when mixed parasitic infections 
caused by roundworms and coccidia are suspected 
or demonstrated. Toltrazuril is a symmetrical tri-
azinetrione and has been used as a coccidiocide 
in veterinary medicine since the 1980s. It has 
broad-spectrum activity against species of vari-
ous genera of coccidia, e.g. Eimeria and Isospora, 
and acts against all intracellular developmental 
stages of schizogony and gamogony by interfer-
ing with the respiratory chain and DNA synthe-
sis (Haberkorn and Stoltefuss 1987; Harder and 
Haberkorn 1989). 
The efficacy of the suspension against nematodes 
(Toxocara canis, Ancylostoma caninum, Uncinaria 
stenocephala) due to the nematocidal compound 
emodepside has been demonstrated in a series of 
laboratory dose-confirmation studies (Schimmel 
et al. 2011). The present work reports the results of 
three controlled laboratory studies that evaluated 
the efficacy of emodepside plus toltrazuril suspen-
sion against prepatent and patent infections with 
I. canis and I. ohioensis-complex in dogs.
Materials and methods
Study design
The studies were conducted according to good clini-
cal practice as described in VICH guideline 9. Each 
study contained two treated groups and one control 
group. The first group was treated 2 or 4 days after 
experimental infection to investigate efficacy of the 
formulation against prepatent Isospora spp. infec-
tion. In the second group, dogs were individually 
treated one day after the faecal oocyst count (FOC) 
had reached a defined level, the “FOC threshold” 
FOCT [≥ 500 or > 1,000 oocysts per gram faeces 
(OPG)], to evaluate efficacy of the formulation 
against patent Isospora spp. infections. The control 
group was treated with placebo at the same time as 
the first treatment group. The primary variable to 
determine efficacy were the FOC of treated dogs in 
comparison to control dogs (see below). The study 
designs are summarised in Tab. 1.
Study animals
Pregnant, purpose-bred Beagle bitches were 
obtained from different suppliers so that the pup-
pies to be enrolled in the three studies were born 
at the test facilities and acclimatised to the study 
conditions. The puppies were identified by subcu-
taneously implanted microchips. 
Litter mates were housed together with the bitch 
throughout the studies except for study III, where 
one litter had to be weaned 7 days post infection 
(dpi) because the bitch developed clinical signs of 
coccidiosis that required treatment. In study II 
three puppies were cross-fostered by one of the 
bitches to another prior to study start so that litters 
were of similar size. Puppies received supplemen-
tal commercial dog food two or three times daily 
and water was available ad libitum.
S12
Procox®
General requirements for study inclusion were 
good health and no recent drug treatment that 
could potentially interfere with the study.
Clinical observations
In all studies dogs were physically examined at least 
once before experimental infection and once before 
treatment. Additionally, all dogs were observed 
for their general health once daily. On treatment 
days clinical assessments with the aim to detect 
adverse events were conducted once before treat-
ment and approximately 0.5, 1, 2, 3, 4 and 8 hours 
after treatment. 
Infection
When the puppies were 3 – 5 weeks of age, they were 
orally infected with sporulated oocysts of I. canis 
and/or I. ohioensis-complex that had been cultivat-
ed at Bayer Animal Health GmbH or the University 
of Veterinary Medicine Vienna, Austria, originating 
from puppies of the colony of Bayer Animal Health 
GmbH or from diagnostic field samples from dogs 
in Austria. In study I dogs showed a natural I. ohio-
ensis-complex infection which could also be included 
in the efficacy evaluation in addition to the experi-
mental I. canis infection. The inoculation doses 
used for infection are shown in Tab. 1. In study II 
lower inoculation doses were chosen to avoid seri-
ous health complications in the puppies, as experi-
mental infections have been shown to be potentially 
more pathogenic if I. canis and I. ohioensis-complex 
are combined (Becker et al. 1981).
Treatment
Within the litters puppies were randomly assigned 
to one of the three study groups so that each litter 
contained treated and control puppies. The puppies 
were treated once with emodepside plus toltrazuril 
suspension or placebo suspension. Treatment was 
applied at set times after experimental infection 
(2 or 4 days after experimental infection) for groups 
that were to be treated during prepatency and 
individually applied the day after FOCT had been 
reached for dogs that were to be treated during a 
patent Isospora spp. infection (see Tab. 1). 
In all studies the minimum therapeutic dose of 
0.45 mg emodepside and 9 mg toltrazuril per kg 
body weight was administered based on the body 
weights taken on the day of treatment. The suspen-
sion was orally applied using a syringe. The dogs 
were observed at dosing and ~ 30 minutes after 
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It was attempted to collect individual faeces from 
the puppies on the day before the experimental 
infection and daily at least from 5 dpi until the 
end of the respective study (for detailed sampling 
days refer to Tab. 1). Due to the young age of the 
puppies, it was not possible to obtain faeces each 
day from each puppy. Individual samples were 
obtained either by placing the puppies into indi-
vidual boxes for defaecation or by gentle manipu-
lation of the anal sphincter with a cotton swab to 
initiate defaecation.
The consistency of faeces was observed directly 
after collection of faeces. The faeces were assessed 
as normal/loose (as some variation in faecal con-
sistency was considered to be normal in puppies), 
diarrhoea or watery diarrhoea. Blood was noted if 
present. Faeces were stored at room temperature 
and FOC were conducted within 3 days after collec-
tion using modified McMaster techniques. 
Efficacy determination and statistical analysis 
The primary variable for the evaluation of efficacy 
against Isospora spp. were the FOC of treated dogs 
in comparison to the control group.
Efficacy was described using two methods: 
–  % reduction for each day where FOCT was reached 
in at least 6 control dogs (> 1,000 OPG in studies 
I and III; ≥ 500 OPG in study II because of the 
lower inoculation dose) and 
 –  The days where statistically significant differ-
ences (p < 0.05) to the control group were seen, 
independently from specific requirements for 
infection of the control group.
For the group that received the treatment during 
patency, the data were analysed relative to the day 
of treatment instead of the study day, as the dogs 
were individually treated after passing the respec-
tive FOCT so that within the group dogs had been 
treated on different study days. Similarly, for the 
comparison between treated and control group the 
data in the control group were analysed relative to 
the day when the individual dogs would have been 
treated had they been in the treatment group. 
Percent efficacy was calculated per study day 
(group 1) or “day relative to treatment” (group 2) 
according to the following formula:





Geometric means were calculated following trans-
formation using a logarithmic method (averaging 
the transformed values, and converting the average 
using anti-log to represent a geometric mean). The 
non-parametric Wilcoxon rank sum test (two sided, 
using α = 0.05) was used to test for both gender and 
treatment group effects across all study days.
In study II an additional analysis was performed 
using a parametric test on ranked oocyst counts. 
The analysis of the treatment during prepatency 
involved a repeated measures analysis of variance 
(RMANOVA) on the rankings. For the analysis 
of the treatment during patent infection a base-
line covariate [average of the day before and the 
day of treatment log oocyst counts (+1)] was used 
in a repeated measures analysis of covariance 
( RMANCOVA). If a statistically significant treat-
ment by day interaction was seen, treatment effects 
were determined for each study day. If no statisti-
cally significant treatment by day interaction was 
seen, an overall treatment effect was determined 
for the overall post treatment period.
The analyses were performed using SAS software 
(SAS® Institute, Cary, NC, USA).
As a secondary criterion, faecal consistency was 
evaluated by comparing the number of observations 
of diarrhoea (i.e. diarrhoea ± blood, watery diar-
rhoea) in each group using the Wilcoxon Rank Sum 
test (two-sided, using α = 0.05). The test results 
were regarded as significant if the lower bound of 
the two-sided confidence interval of the  Wilcoxon 
Rank Sum test was > 0.5 (equality line). The results 
were interpreted only in a descriptive manner 
because no alpha-adjustment for multivariate test-
ing was performed. The analysis was performed 





In the control groups of studies I and II prepatency 
after I. canis infection was 8 – 12 days and indi-
vidual oocyst excretion was observed on 7 – 11 days 
with 9 of 17 dogs still shedding oocysts at the end 
of the studies. During patency, individual oocyst 
numbers ranged between 0 – 1 x 106 OPG in study 
I and 0 – 3.7 x 105 OPG in study II. The peak of 
oocyst shedding was observed 12 dpi (study I) 
or 13 dpi (study II) with geometric mean oocyst 
counts of 110,238 OPG (study I) and 18,898 OPG 
(study II).
In the control groups of studies II and III prepa-
tency after experimental infection with I. ohio-
ensis-complex was 3 – 6 days. Patent infection was 
demonstrated on 5 – 17 days with 9 of 16 dogs still 
showing a patent infection at the end of the studies. 
During patency, individual oocyst numbers ranged 
between 0 – 7 x 104 OPG (study II) and 67 – 1.8 x 
105 OPG (study III). Peak shedding was observed 
6 dpi (study III) or 7 dpi (study II) with geometric 
mean oocyst counts of 6,437 OPG (study III) and 
5,952 OPG (study II). A second, weaker peak was 
observed 13 dpi in study II with a geometric mean 
oocyst count of 2,251 OPG.
The intervals where at least 6 dogs in the control 
group passed FOCT are shown in Tabs. 2 and 3.
Efficacy evaluation  
and clinical observations
The efficacy of emodepside plus toltrazuril suspen-
sion against prepatent I. canis infection was dem-
onstrated in studies I and II (Tab. 2, Figs. 4 and 5). 
On days when at least 6 control dogs passed FOCT, 
oocyst counts were reduced by 90.2 – 100 % in treat-
ed dogs. Significantly lower oocyst counts of the 
treated dogs were observed for 5 – 7 days. In study 
II efficacy was demonstrated for up to 12 days after 
treatment (14 dpi). For the following three days 
where the control group still showed at least 6 dogs 
with counts above FOCT, no significant differences 
were seen between the FOC of the treated and con-
trol group (Fig. 5).
Treatment with emodepside plus toltrazuril sus-
pension against patent I. canis infection reduced 
FOC by 91.5 – 100 %, and significantly lowered 
oocyst counts were observed for 5 to 9 days in treat-
ed dogs compared to the control group (Tab. 2). In 
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study II efficacy on the day after treatment was 
77 % but then was ≥ 91.5 % for the following days.
The efficacy of the suspension against prepatent 
Isospora ohioensis-complex infection could be eval-
uated in all three studies including study I where 
a natural I. ohioensis-complex infection had arisen 
during the study. The studies demonstrated FOC 
reductions between 99.7 % and 100 % and signifi-
cantly lower oocyst counts for 5 – 12 days compared 
to the control group (Tab. 3, Figs. 6 – 8). 
In study III treatment was applied on the day after 
oocyst counts of I. ohioensis-complex had reached 
FOCT, while treatment in study II (where  animals 
had been experimentally infected with both Isos-
pora spp.) had been targeted at patent I. canis 
infection so that at the time of treatment the dogs 
had been patent for I. ohioensis-complex for some 
days already. The two studies demonstrated FOC 
reductions of 99.2 % and 99.9 % and significantly 
lower oocyst counts for 4 – 9 days compared to the 
control group (Tab. 3). 
In all three studies the number of days with diar-
rhoea was significantly reduced when dogs were 
treated during prepatent Isospora spp. infection 
compared to the control groups (Fig. 9). No differ-
ences in the frequency of diarrhoea were seen when 
dogs were treated only after the Isospora spp. infec-
tion had become patent.
No adverse drug reactions were observed during 
the studies.
Discussion 
The infections that developed in the control groups 
following the experimental inoculation of animals 
with I. canis and/or I. ohioensis-complex were com-
parable to published data with regard to length of 
prepatency/patency and peak of oocyst shedding 
(Becker et al. 1981; Daugschies et al. 2000; Buehl 
et al. 2006; Mitchell et al. 2007). The wide ranges 
for oocyst excretion illustrate the variability typical 
for coccidial infections and also compare to previ-
ous data (Daugschies et al. 2000; Mitchell et al. 
2007). I. canis generally appeared to lead to higher 
oocyst excretion than I. ohioensis-complex. Similar 
observations were described by Buehl et al. (2006), 
who discussed this finding as a possible result 
of additional schizogony stages of I. canis. For 
I. canis, oocyst excretion tended to be higher after 
a higher inoculation dose, as higher oocyst excre-
tion was observed in study I compared to study II. 
Tab. 3  Results of studies on the efficacy against I. ohioensis-complex
Treatment Study no.
Interval of  
adequate  infectiona 
in control group
Interval of significant  





I 6–7 dpi 6–10 dpi 99.7 %  (p ≤ 0.025)
II 6–8, 12–13 dpi 5–16 dpi 99.8–100 % (p ≤ 0.011)
III 5–8 dpi 5–11 dpi 99.9–100 % (p ≤ 0.012)
During  
patency
II 1 dpt 1–9c dpt 99.2 %  (p = 0.0028)c














































































































































































































































































In contrast, the differences in the oocyst excretion 
were less striking between the inoculation doses 
used for I. ohioensis-complex in studies II and III. 
Interestingly, a second peak was observed 13 dpi for 
FOC of I. ohioensis-complex in study II, where dogs 
were co-infected with I. canis. This peak coincided 
with the peak for I. canis so that the combination of 
the two pathogens may have altered the excretion 
pattern of I. ohioensis-complex and thus have pro-
longed patency of I. ohioensis-complex. This would 
differ from the data of Buehl et al. (2006), where 
no differences had been observed in the excretion 
patterns of the two species after a mixed infection.
High efficacy against prepatent I. canis and I. ohio-
ensis-complex infection was demonstrated in all 
three studies. However, in study II there were no 
significant differences between the I. canis oocyst 
counts of treated and control dogs from 15 to 
17 dpi while the requirement for at least 6 control 
dogs reaching FOCT was still fulfilled. This could 
be interpreted as a fading efficacy from 12 days 
post treatment onwards so that another toltra-
zuril treatment could be indicated approximately 
2 weeks after the first treatment to ensure contin-
ued efficacy. However, it should be considered that 
puppies were randomised within litters, with the 
result that treated puppies had access to faeces of 
their untreated littermates. Freshly shed oocysts 
are not infective so that after ingestion they merely 
pass through the intestines and cannot be distin-
guished from oocysts that truly originate from an 
infection of the sampled individual. This possibility 
was previously considered by Buehl et al. (2006), 
who similar to our experimental setup had accept-
ed group housing of litters containing treated and 
untreated puppies as a potential confounding effect 
in the interest of animal welfare and sound ran-
domisation practice. Also, study I had yielded very 
clear results regarding efficacy against I. canis 
with comparatively strong infection of the control 
group. The metaphylactic efficacy against experi-
mental as well as natural infection with I. ohio-
ensis-complex shown in the studies is further 
supported by a study of Daugschies et al. (2000), 
where toltrazuril was applied to puppies 3 dpi with 
I. ohioensis-complex. The control dogs showed fae-
cal oocyst counts between 800 and 118,200 OPG 
while no oocyst excretion was found in dogs treated 
with 10 mg toltrazuril per kg body weight. 
Emodepside plus toltrazuril also showed a high 
efficacy against patent infections with I. canis and/
or I. ohioensis-complex. The calculated 77 % reduc-
tion of I. canis FOC in study II on the first day 
after treatment is considered to be due to the time 
required for intestinal passage of oocysts. On the 
first day after treatment, faecal samples can still 
contain “pre treatment” faeces so that FOC reduc-
tion may take a day to become fully evident. This 
had also previously been observed by the authors 
in pilot studies (unpublished data). 
In addition to the direct effect on FOC, signifi-
cantly lower occurrence of diarrhoea was observed 
when dogs were treated during prepatency in 
comparison to the control group. No such differ-
ences were seen when dogs were only treated 
after the infection had become patent. In Isospora 
spp. infection diarrhoea develops as a result of 
the enteritis caused by mucosal damage during 
schizogony and gamogony. The onset of diarrhoea 
is typically observed shortly before the beginning 
of oocyst excretion (Mitchell et al. 2007; Lappin 
2010). Consequently, if an anticoccidial treatment 
is applied only after the shedding of oocysts it can-
not reverse the damage caused by the endogenous 
development of the parasites. Depending on the 
severity of clinical signs additional treatment may 
be indicated, e.g. fluid therapy against dehydra-
tion and possibly antibiotic therapy to prevent or 
treat secondary bacterial infections that may arise 
from the intestinal mucosal damage. A certain 
degree of diarrhoea was still observed in the dogs 
treated during prepatent Isospora spp. infection 
in the three studies. The puppies were not tested 
for other potential causes of enteritis like bacteria 
and viruses so that it is unknown whether such 
agents may have contributed to occurrence of diar-
rhoea in the study populations. In any case, the 
significantly lower frequency of diarrhoea supports 
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that early treatment of Isospora spp. infection can 
have a marked effect on the clinical implications 
of the infection. Similarly, Daugschies et al. (2000) 
observed that treatment of puppies 3 days after 
experimental infection with I. ohioensis-complex 
effectively suppressed haemorrhagic diarrhoea 
which was seen in the untreated control dogs. 
The three laboratory studies demonstrated high 
efficacy of emodepside plus toltrazuril suspension 
against I. canis and I. ohioensis-complex. As it is 
not possible to clearly determine the stage of infec-
tion in practice, efficacy was demonstrated choos-
ing various time points for treatment to cover a 
wide range from early prepatent to fully developed 
patent infection. Two field studies complemented 
the picture under natural conditions showing 
99 – 100 % efficacy of emodepside plus toltrazuril 
suspension against prepatent or patent Isospora 
spp. infection based on FOC reduction in compari-
son to an untreated control or a reference product 
(Altreuther et al. 2011). The data confirmed that 
from an epidemiological as well as a clinical point 
of view it makes sense to treat at an early stage 
of infection to minimise oocyst shedding as well 
as intestinal mucosal damage. As Isospora spp. 
are primarily spread within and between litters 
by infected mates (Daugschies et al. 2000), it is 
advisable to treat all dogs within a group where 
infection is suspected. In contrast to coccidia infec-
tions of other species, e.g. Isospora suis in pigs, no 
exact pattern for Isospora spp. infection has been 
observed for the dog. Buehl et al. (2006) found that 
already 3 week old puppies had been infected and 
Isospora could still be identified in puppies shortly 
before weaning in the 10th week of life with a peak 
around the 7th week of life. Daugschies et al. (2000) 
reported the highest probability of oocyst excretion 
in puppies of 4 – 6 weeks of age based on evaluations 
conducted at several commercial dog breeders. 
However, also stressful situations like shipping, 
weaning or change in ownership are described to 
lead to repeated oocyst shedding and potentially 
clinical disease in puppies that have been exposed 
to Isospora spp. (Dubey et al. 2009; Lappin 2010) so 
that each treatment should be decided considering 
the situation of the individual puppy. If anticoccidi-
al treatment needs to be repeated, emodepside plus 
toltrazuril suspension can be used if there is a con-
comitant need for deworming, e.g. in puppies that 
are treated against Toxcara canis according to the 
recommendation of the European scientific counsel 
companion animal parasites (ESCCAP 2010).
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